# Insertional mutagenesis

Source: https://onco.cc/terms/insertional-mutagenesis/  
OnCo record `insertional-mutagenesis` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Insertional mutagenesis is a change in a cell's genes caused by added genetic material landing in its DNA and disrupting a gene or its control, and neither an insertion nor a growing cell clone shows by itself that a cancer has formed or what caused it.

## Summary

Some gene delivery systems, including the viral vectors used to make engineered T cells and to correct inherited immune disorders in blood stem cells, insert a genetic cassette into the cell's genome. Integration is the event; insertional mutagenesis is a consequential change that the event causes, such as interrupting a gene or altering the activity of a nearby one. Integration alone does not establish a harmful biological consequence. A cell that gains a growth advantage passes the insertion to its descendants and a clone expands, but a growing clone is not a diagnosis of cancer, because a useful therapeutic response can also expand a clone. FDA's long-term follow-up guidance for gene therapy (January 2020) explains why the question is taken seriously: the biological activity of retroviral vectors and transposon elements is imparted by an integration event, such integration is in general not directed to specific sites, and that raises the potential for disruption of critical host genes or activation of proto-oncogenes near the site, and so the risk of malignancy. A nonviral transposon is therefore also an integrating system, and genome editing can produce its own undesirable changes with a risk of malignancy, which is a separate mechanism from vector insertion.

Three primary reports show why the setting matters. After retrovirus-mediated gamma-c gene transfer into autologous CD34-positive bone marrow cells for X-linked severe combined immunodeficiency, 9 of 10 patients were corrected, but almost three years later the two youngest developed uncontrolled clonal proliferation of mature T cells; both clones carried vector integration near the LMO2 proto-oncogene promoter with abnormal LMO2 expression, which the authors attributed most likely to retrovirus enhancer activity (Hacein-Bey-Abina et al., 2003). In a patient with chronic lymphocytic leukaemia given CD19 CAR T cells, 94 per cent of CAR T cells at the peak of response came from one clone in which lentiviral insertion had disrupted TET2, the patient's second TET2 allele carried a hypomorphic mutation, and the clone showed a central memory phenotype alongside complete remission: an expanded clone linked to benefit, not a new cancer (Fraietta et al., 2018). In 724 patients treated with T-cell therapies at one centre, a lethal T-cell lymphoma followed axicabtagene ciloleucel for diffuse large B-cell lymphoma; the tumour, the CAR T cells and the patient's normal blood cells were profiled in depth, both lymphomas were Epstein-Barr virus positive and linked to DNMT3A and TET2 mutant clonal haematopoiesis, and no evidence of oncogenic retroviral integration was found with multiple techniques (Hamilton et al., 2024). The first is a specific stem-cell regimen and the others are single-centre or single-patient observations, so none is an incidence estimate for a vector or product.

What regulators ask for follows from this. The ABECMA prescribing information revised in November 2025 carries a boxed warning that T-cell malignancies, including CAR-positive tumours, have occurred after BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies for blood cancers, may present within weeks of infusion and may be fatal, and says to monitor life-long for secondary malignancies. FDA's CAR T-cell development guidance recommends following people for 15 years after treatment with CAR T cells containing an integrated transgene, because integrating vectors may increase the risk of delayed adverse events and non-integrating vectors are thought to carry a low delayed risk. These are class-level product warnings and follow-up expectations; they do not assign one mechanism to every event or give an incidence for other products.

To attribute a malignancy after engineered-cell therapy, investigators ask whether the therapeutic sequence is present in the malignant cells, where the integrations are, whether they alter relevant genes, whether related clones were detectable earlier, and what prior therapy, underlying disease and pre-existing genetic changes contribute. Integration-site sequencing maps insertion locations, quantitative DNA assays estimate vector copies per cell, and flow cytometry, gene-expression measurement and pathology answer different questions about identity, function and malignancy; the sample is consumed by testing. Average vector copy number cannot show the position or effect of each insertion, a clone's frequency depends on the sampled cells, assay sensitivity and time, and blood may not represent every tissue. This record gives no copy-number or clone-frequency threshold because none of the sources read sets one. Messenger RNA delivery that does not integrate does not use genomic insertion as its route, which does not remove its other risks.

## Fields

- Kind: Term
- Last checked: 2026-11-16
- Also known as: insertional oncogenesis; vector insertional mutagenesis; vector integration site analysis

## Notes

- In a fictional follow-up example, an engineered-cell clone becomes more common but no new malignancy has been established. The observation prompts examination of the clone, insertion sites, gene effects and clinical findings. A growth pattern, a malignant diagnosis and an insertion-driven mechanism are separate claims. An insertion that leaves no demonstrated gene effect, one that interrupts a gene and one that alters nearby regulation are different possibilities; none of those schematic locations assigns an incidence or time to cancer. A CAR-positive malignancy can establish product ancestry without identifying which change drove it.
- Hamilton’s secondary T-cell-lymphoma case followed axicabtagene ciloleucel. The NCI Drug Dictionary describes that product’s gammaretroviral vector; it should not be relabelled as a lentiviral product. The study found no evidence of oncogenic retroviral integration in the deeply profiled case. Product identity, the diagnosis and investigation of its cause remain separate; that finding does not negate the malignancy warning or estimate the risk of every other integrating system.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Insertional_mutagenesis
- Wikipedia: https://en.wikipedia.org/wiki/Insertional_mutagenesis
- Hacein-Bey-Abina et al., LMO2-associated clonal T cell proliferation after gene therapy for SCID-X1 (2003): https://pubmed.ncbi.nlm.nih.gov/14564000/
- Fraietta et al., disruption of TET2 promotes the efficacy of CD19-targeted T cells (2018): https://pubmed.ncbi.nlm.nih.gov/29849141/
- Hamilton et al., second tumors and T-cell lymphoma after CAR T-cell therapy (2024): https://pubmed.ncbi.nlm.nih.gov/38865660/
- ABECMA prescribing information (FDA): https://www.fda.gov/media/147055/download
- FDA: long term follow-up after administration of human gene therapy products (guidance, January 2020): https://www.fda.gov/media/113768/download
- ABECMA prescribing information, November 2025 revision (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c
- NCI Drug Dictionary: axicabtagene ciloleucel: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/768723

## Connected records

- terms: [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [LMO2](https://onco.cc/targets/lmo2/), [TET2](https://onco.cc/targets/tet2/)

---
JSON: https://onco.cc/api/v1/entities/insertional-mutagenesis.json